Evidence map›Paper›PMID 42823723›Full record

ArticleJournal of intensive care2026

Subphenotype-specific serum proteomic signatures in patients with ARDS.

Michihito Kyo, Masashi Kawami, Yasuo Uchida, Kazuya Kikutani, Daisuke Kasugai, Shinichiro Ohshimo, Nobuyuki Hirohashi, Nobuaki Shime

Abstract read
In one paragraph

Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Michihito KyoDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan. mkyo@hiroshima-u.ac.jp.ORCID https://orcid.org/0000-0002-2559-6440
Masashi KawamiDepartment of Pharmaceutics, School of Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
Yasuo UchidaDepartment of Molecular Systems Pharmaceutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kazuya KikutaniDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Daisuke KasugaiDepartment of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Shinichiro OhshimoDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.
Nobuyuki HirohashiDepartment of Radiation Disaster Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Nobuaki ShimeDepartment of Emergency and Critical Care Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-Ku, Hiroshima, 734-8551, Japan.

Funding

Japan Society for the Promotion of Science 25H02462Japan Society for the Promotion of Science 25K12297Japan Society for the Promotion of Science 26K02503
6 · The paper itself

Abstract

backgroundAcute respiratory distress syndrome (ARDS) is associated with a substantial burden of morbidity and mortality. Previous studies have identified reproducible hyperinflammatory and hypoinflammatory ARDS subphenotypes with distinct clinical outcomes and treatment responses. Although recent transcriptomic studies have provided insights into biological differences between these subphenotypes, the role of the circulating proteome remains incompletely understood.

methodsIn this prospective study, patients with ARDS were classified into hyperinflammatory or hypoinflammatory subphenotypes using a previously validated 3-variable classifier based on bicarbonate, interleukin-6, and soluble tumor necrosis factor receptor 1. Serum proteomic profiling was performed to identify differentially abundant proteins between subphenotypes. Biological pathways were examined using gene set enrichment analysis. To provide cellular expression context for the subphenotype-associated serum proteins, serum proteomic data were mapped onto publicly available single-cell RNA-seq datasets from peripheral blood mononuclear cells, neutrophils, and tracheal aspirates.

resultsAmong 31 patients with ARDS, 13 (42%) were classified as having the hyperinflammatory subphenotype and 18 (58%) as having the hypoinflammatory subphenotype. Both 28-day and in-hospital mortality were higher in the hyperinflammatory subphenotype than in the hypoinflammatory subphenotype (46% vs. 11%, P=0.04; 62% vs. 11%, P=0.01, respectively). In total, 54 serum proteins were differentially abundant between subphenotypes. These proteins represented biologically relevant categories, including endothelial injury, immunoregulation, coagulation/fibrinolysis, complement regulation, tissue remodeling, and metabolism-related proteins. Gene set enrichment analysis identified pathways differentially enriched between subphenotypes, including cell adhesion, cell-cell signaling, and cytokine responses (all FDR < 0.10). In external single-cell RNA-seq reference datasets, genes encoding the subphenotype-associated proteins were expressed predominantly in CD14 and CD16 monocytes in PBMCs, showed distinct expression patterns across immature and CD163+IL1R2^hi^ circulating neutrophil states, and were expressed mainly in macrophage and monocyte populations, with additional epithelial expression, in tracheal aspirates.

conclusionsSerum proteomic profiling identified distinct protein patterns associated with established ARDS inflammatory subphenotypes, providing insights into the biological heterogeneity of ARDS.

Indexed as

ARDSMyeloidProteomeSubphenotype

Identifiers

PMID42823723
PMCPMC13628812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.